News
HERZLIYA, Israel and CALGARY, Alberta, July 23, 2025 /PRNewswire/ -- Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that ...
Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has publicly filed a registration statement on Form F-1 with the U.S.
Current approaches in bioengineering are synthesized and methods for their implementation are suggested for the induction and modulation of trained immunity in the treatment of human diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results